Nippon Shinyaku and Johnson & Johnson start co-promotion of Opsumit pediatric tablets in Japan
Reuters
Mar 18
<a href="https://laohu8.com/S/NPPNY">Nippon Shinyaku</a> and Johnson & Johnson start co-promotion of Opsumit pediatric tablets in Japan
Nippon Shinyaku began co-promotion activities with Johnson & Johnson for Opsumit Pediatric Dispersible Tablets in 1 mg and 2.5 mg. The tablets are indicated for pediatric pulmonary arterial hypertension in patients aged 3 months and older. The products received approval from Japan’s MHLW on December 22, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on March 18, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.